Aadi Bioscience to Participate in the Jefferies Healthcare Conference

Rhea-AI Summary

Aadi Bioscience (NASDAQ: AADI), a commercial-stage precision oncology company, announced its participation in the Jefferies Healthcare Conference in New York on June 5-6, 2024.

CEO Dave Lennon, Ph.D., will be involved in a fireside chat scheduled for June 5, 2024, from 2:00 PM to 2:25 PM EDT. The event will be webcast live on Aadi Bioscience's investor relations webpage and available for replay for 30 days.

Positive

• Aadi Bioscience's participation in the Jefferies Healthcare Conference may increase investor visibility and interest.
• CEO Dave Lennon's involvement in a fireside chat highlights leadership engagement and transparency.

Negative

• No immediate financial or clinical data updates were provided, leaving investors without new data-driven insights.
• The announcement lacks specifics about potential business development or partnerships to be discussed at the conference.

LOS ANGELES, May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, announced today participation in the Jefferies Healthcare Conference, taking place June 5-6, 2024, in New York. Dave Lennon, Ph.D., President and CEO, will participate in a fireside chat on Wednesday, June 5, 2024, from 2:00 PM – 2:25 PM EDT.

The fireside chat will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following each investor event.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. To unlock the full potential of mTOR inhibition, Aadi uniquely combines nanoparticle albumin-bound (nab) technology with the potent mTOR inhibitor, sirolimus. Aadi received FDA approval and commercializes FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi is exploring nab-sirolimus in PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. Aadi is also exploring nab-sirolimus in two single-indication Phase 2 trials for difficult-to-treat mTOR-driven cancers: neuroendocrine tumors (NETs), and advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
IR@aadibio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-participate-in-the-jefferies-healthcare-conference-302158555.html

SOURCE Aadi Bioscience

FAQ

When is Aadi Bioscience participating in the Jefferies Healthcare Conference?

Aadi Bioscience will participate in the Jefferies Healthcare Conference on June 5-6, 2024.

What is Aadi Bioscience's stock symbol?

Aadi Bioscience's stock symbol is AADI.

Who will represent Aadi Bioscience at the Jefferies Healthcare Conference?

CEO Dave Lennon, Ph.D., will represent Aadi Bioscience in a fireside chat.

Will the Aadi Bioscience fireside chat be available online?

Yes, the fireside chat will be webcast live on the Aadi Bioscience website and available for replay for 30 days.

What time is Aadi Bioscience's fireside chat at the Jefferies Healthcare Conference?

The fireside chat is scheduled for June 5, 2024, from 2:00 PM to 2:25 PM EDT.